Aurora B, a kinase that phosphorylates H3, has also been implicated in treatment resistance in NSCLC, with nonmitotic levels of phospho-H3 being increased by EGFR-TKI treatment [23]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.